PDX model details
| PDX ID | 422M Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
7 (2*) |
| Average PDX Generation Time (days +/- SEM) | 184 ± 72 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 422M Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | Y |
| ERG | Y |
No information in CNV Table
Clinical Information
| Sample Number | 422M |
|---|---|
| Sample Site | Brain |
| Sample source | Surgery |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 422 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 422M |
| Patient Age (binned in 5 year age groups) | 70-74 |
No information in Mutation Table
No information in Gene expression
No information in Drug dosing Table